On March 21, 2000 the head of the FDA's Center for Drug Evaluation and Research (CDER) stated that "continued use of Rezulin posed an unacceptable risk to diabetes patients." This was not first time the drug's dangers were called into question. In 1996, during the FDA approval stage, the lead medical officer cited Rezulin as potentially harming to the liver and the heart. The drug, however, was approved in January 1997. By fall of 1997, dozens of patients on Rezulin were hospitalized and cases of hepatocellular cancer, ...MORE >>
